08:00 , Dec 19, 2005 |  BC Week In Review  |  Clinical News

NMP66 diagnostic data

In a study comparing serum from breast cancer patients and healthy women, the NMP66 complex was detected in each cancer patient serum sample and was absent in each healthy subject sample. There was a 67%...
07:00 , May 30, 2005 |  BC Week In Review  |  Clinical News

Matritech preclinical data

In 298 blinded serum samples, the qualitative RT-PCR test to detect nuclear matrix protein NMP66 identified over 70% of the cancer sera. The colorimetric assay showed good differentiation of noncancer samples as 80% of those...
08:00 , Jan 3, 2005 |  BC Week In Review  |  Clinical News

NMP66 diagnostic data

In 20 specimens from breast cancer patients, NMP66 test detected 7 of 8 cancers. Data were presented at the Breast Cancer meeting in San Antonio. Matritech Inc. (MZT), Newton, Mass.   Product: NMP66   Business:...
07:00 , Sep 27, 2004 |  BC Week In Review  |  Company News

Matritech other research news

Preliminary data from a serum-based NMP66 RT-PCR test detected the presence of the NMP66 protein complex in 13 of 14 samples from cancer patients and in 19 of 36 samples from patients with benign or...
07:00 , Oct 21, 2002 |  BC Week In Review  |  Company News

Matritech, Mitsubishi Chemical Corp. deal

NMPS and Mitsubishi Chemical subsidiary Mitsubishi Kagaku Medical partnered to complete development of NMPS's NMP66 breast cancer blood test. Under the deal, NMPS will conduct an initial validation study using Mitsubishi specimens from Japanese women....
07:00 , May 28, 2002 |  BC Week In Review  |  Company News

Matritech, Bruker Daltonics deal

The companies partnered to automate BDAL's mass spectrometry systems to run NMPS's NMP66 and NMP48 blood tests for breast and prostate cancer, respectively. Matritech Inc. (NMPS), Newton, Mass.   Bruker Daltonics Inc. (BDAL), Billerica, Mass....
07:00 , Jun 18, 2001 |  BC Week In Review  |  Clinical News

NMP66: Began trial

Matritech Inc. (NMPS), Newton, Mass.   Product: NMP66   Business: Diagnostics/Imaging   Therapeutic category: Test   Target: Nuclear matrix protein   Description: Diagnostic test for nuclear matrix protein NMP66 that regulates pre-mRNA splicing   Indication:...
07:00 , May 29, 2001 |  BC Week In Review  |  Clinical News

NMP66: Began Trial Enrollment

Matritech Inc. (NMPS), Newton, Mass.   Product: NMP66   Business: Diagnostics/Imaging   Therapeutic category: Test   Target: Nuclear matrix protein   Description: Diagnostic test for nuclear matrix protein NMP66 that regulates pre-mRNA splicing   Indication:...
08:00 , Jan 2, 2001 |  BC Week In Review  |  Clinical News

Nuclear matrix protein regulatory update

NMPS received U.S. Patent No. 6,162,608 covering the detection of NMPs in bodily fluids, including blood, urine, spinal fluid and sputum, to detect cancer. The company said the patent covers its marketed NMP22 bladder cancer...
07:00 , Jun 5, 2000 |  BC Week In Review  |  Clinical News

NMP66 test kit: Proof of concept study

In 45 specimens from breast cancer patients, NMPS said that its test detected NMP66 in all samples, including those with newly diagnosed metastatic disease and those with no lymph node involvement. The product also detected...